AlphAIAlphAI — Financial news for AI agents
investing.comNOV 22 min read$TEM

Why is Tempus AI stock rallying today?

Tempus AI stock rose 3.2% in pre-market trading after its Q3 2026 results beat expectations, with revenue of $411.5M (up 23% YoY) and adjusted EPS of $0.07. The company raised its full-year revenue guidance to $1.60–$1.605B. The broader market also showed gains, with the S&P 500 and Nasdaq up 0.4% and 0.7%, respectively.

Original reporting
investing.com
Published Nov 2, 2026, 1:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 1:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$TEM
Bullish
high confidence
Mentioned
$TEM
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TEMBullishHigh
01

Why it matters

The earnings beat reinforces the company's growth narrative and may attract additional capital inflows.

02

Market read

Fresh earnings data with a beat and guidance raise provide a clear catalyst for short‑term trading.

03

What to watch

Potential regulatory scrutiny on AI diagnostics or slower adoption could temper upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Tempus AI operates in AI‑enabled oncology diagnostics and data services, a fast‑growing niche within health‑tech.

Company-level read

Ticker impact

$TEMBullishHigh confidence
Context

Tempus AI reported Q3 2026 earnings beat and raised full-year revenue guidance, driving a 3.2% pre‑market rally.

Expected impact

upward pressure as investors price in the beat and higher guidance

Evidence & confidence

The surprise EPS beat and 23% revenue growth, plus upgraded guidance, are fresh material that typically fuels buying.

Market effects

Sector

Strong AI‑driven diagnostics earnings may lift other health‑tech and AI‑enabled biotech stocks.

Regional

U.S. tech sector gains modestly as the earnings beat supports broader AI optimism.

Global

Limited to U.S. markets; no immediate global macro effect.

Counterpoint

What could challenge this read

If the beat is already priced in, the stock could face short‑term profit‑taking.

Key entities

  • Company
    Tempus AI

    AI‑driven diagnostics and data platform.

Read at source← All news

StoryTempus AI posts record Q3 revenue, first adjusted profit and raises full‑year outlook

Also covered by

6 outlets

Related articles

NOV 3
$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

investing.com2 min
NOV 3
$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.

finance.yahoo.com2 min
NOV 2
$TEMMedAI 8/10

Tempus AI (TEM): Oncology Volume Surge and Data Licensing Bookings Signal a Profitable Inflection

Tempus AI (TEM) reported Q3 2026 revenue of $411.5M, up 23% YoY, with adjusted EBITDA of $25.6M. Oncology revenue grew 28% to $172.6M, while Data and Applications revenue increased 33% to $108.1M. The company raised full-year revenue guidance to $1.60B-$1.605B and expects near-term catalysts from reimbursement improvements and the pending $1.7B Personalis acquisition.

news.alphastreet.com7 min